FDA Finalizes Guidance on Co-Crystals in NDAs and ANDAs Post author:Sam Post published:February 14, 2018 Post category:Drug Industry Daily The FDA finalized new guidance establishing co-crystals as a drug product intermediate. Source: Drug Industry Daily You Might Also Like CBER Report Shows Slight Dip in Regenerative Medicine Designation Requests April 11, 2022 PRAC Recommends Contraindication for Zytiga and Xofigo March 9, 2018 EU Releases First Document on New Framework for Data Quality and Integration October 11, 2022